

The Max Planck Institute and Edelris Announce a Research Collaboration

Dortmund and Lyon, February 4th, 2020 - The Max Planck Institute of Molecular Physiology (MPI) and Edelris announce today the launch of a new research collaboration.

Under the terms of the agreement, the aim of the collaboration will be to identify novel ligands towards groundbreaking biological targets.

The biological targets of interest will be selected and provided by the MPI and Edelris will dedicate a privileged access to its EDEN platform (Edelris Discovery ENgine) involving affinity selection screening and a 1M compounds deck inspired by natural products (from Edelris Keymical Space™).

“The understanding of complex biological pathways requires the ability to selectively interact with protein surfaces or disrupt specific protein-protein interactions.” commented Prof. Herbert Waldmann, Director, Chemical Biology at the Max Planck Institute of Molecular Physiology. *“We have demonstrated that such an ambitious goal can be efficiently achieved by means of pseudo-natural products (Pseudo-NPs). The Edelris collection is uniquely positioned to that respect, and we look forward to using their deck and screening technologies against some of our most relevant targets.”*

“We are thrilled to be part of this dynamic collaboration with this world-renowned partner, using our unique technologies and distinctive compound libraries. The project team is highly focused towards solving the high scientific challenges we will be facing.” added Dr Jean-Yves Ortholand, CEO of Edelris.

The terms of the agreement were not disclosed.

About Edelris:

EDELRIIS is a Research & Service based company, dedicated to the acceleration of the hit/lead discovery process for pharmaceutical and biotech organizations. EDELRIIS track-proven chemistry and screening discovery engine provide relevant starting points to its customers' drug discovery programs. The combination of distinctive small molecules libraries and technologies, as well as established hit/lead optimization capabilities have made Edelris the partner of choice for pharmaceutical and biotechnology companies worldwide.